J&J Head of R&D Steps Down Unexpectedly

Mathai Mammen, MD, PhD, has stepped down from his role as head of research and development at Johnson & Johnson. Mammen, who joined the company in 2017, was appointed VP of pharmaceuticals R&D just last year. According to an announcement made yesterday, August 8th, his departure is based on his plans to “pursue other opportunities.”

According to James Waldron, “In his five-year tenure at J&J, Mammen oversaw a move into CAR-Ts that resulted in the approval of Carvykti for myeloma earlier this year. In 2021, he secured a 21% year over year rise in R&D expenditure at the company, with J&J coming close to being named the industry’s top research spender.”

To read more, click here.

(Source: Fierce Pharma, August 9th, 2022)